In 2023, the advent of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tripeptide, which activates both the GIP and GLP-1 receptors, marked another milestone in type 2 diabetes management in Japan (Fig. 1). Here, GLP1R is linked to type 2 diabetes mellitus.